POPULATION PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN HCV/HIV OR HBV/HIV CO-INFECTED INDIVIDUALS J.P. Cruz 1,2, D. Matias 1, C. Carvalho 1, J. Morais.

Slides:

Advertisements

Similar presentations

Hepatitis B & Hepatitis C in HIV

Advertisements

1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.

HAART Highly Active Antiretroviral Therapy

Background  Hypertrigliceridaemia is common in patients with HIV, especially those taking protease inhibitors (PIs) or with lipodystrophy.  Although,

The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.

Mechanistic PBPK as an aid in identifying the size of covariate effects and design of POPPK studies: An example focusing on haematocrit as a determinant.

1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.

Fig 1: HIV-1/HCV and HIV-1/HBV Co-Infection/Co- Culture Systems Philippe A. Gallay 1, Udayan Chatterji 1, Michael Bobardt 1, Daren Ure 2, Dan Trepanier.

Verify or refute the use of Non Linear Mixed Effect Model for Interferon effect on HCV Hila David Shimrit Vashdi Project Advisors: Prof. Avidan Neumann.

Hormonal Contraceptives – Considerations for Women with HIV and AIDS.

Norma I. Rallón 1, José Medrano 1, Salvador Resino 2, Clara Restrepo 1, Vincent Soriano 1 and José M. Benito 1 1 Department of Infectious Diseases, Hospital.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

Washington D.C., USA, July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,

Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania Florida J. Muro, Suzanne P. Fiorillo, Christopher Odhiambo, Coleen K.

World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.

Dose Adjustment in Renal and Hepatic Disease

Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.

Pharmacokinetics of Saquinavir hard gel (Invirase) when combined with Atazanavir 8.11 D Prelutsky 1, P Salvato 2, R Falcon 3 1. Washington University School.

1 Modelling the interactions between HIV and the immune system in hmans R. Ouifki and D. Mbabazi 10/21/2015AIMS.

Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.

PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.

FARMAKOKINETIKA. INTRODUCTION Historically, pharmaceutical scientists have evaluated the relative drug availability to the body in vivo after giving a.

APPLICATION OF INDIVIDUALIZED BAYESIAN UREA KINETIC MODELING TO PEDIATRIC HEMODIALYSIS Olivera Marsenic, Athena Zuppa, Jeffrey S. Barrett, Marc Pfister.

12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.

The effect of fluvoxamine on the pharmacokinetics, and safety of ivabradine in healthy subjects Adina Popa 1, Laurian Vlase 2, Maria Neag 3, Dana Muntean.

Chelsea Harmon Catherine Hanson Abby Llaneza Jen Williams

Distinct hepatitis C virus kinetics in HIV- infected patients treated with ribavirin plus either pegylated interferon α-2a or α-2b Eugenia Vispo, Pablo.

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,

Epidemiology Impaired Glucose Tolerance in HIV-Infected Drug Users By: Odell Aaron La Croix Mentor: Dr. Andrea Howard Work Site:Department of Epidemiology.

INTRODUCTION CLINICAL PHARMACOKINETICS

1 Pharmacokinetics: Introduction Dr Mohammad Issa.

Positive impact of HCV treatment initiation on adherence to HIV treatment in co-infected patients: implications for access to HCV care Roux P 1, Fugon.

Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,

Evaluation of Hepatitis B surveillance system in Armenia, 2014 AUTHORS Karine Gevorgyan Lusine Paronyan Shushan Sargsyan Artavazd Vanyan NCDC, Armenia.

Donepezil. Donepezil Generic name: Donepezil. Brand name: Aricept. Chemistry: Donepezil hydrochloride is a piperidine derivative. It is a white crystalline.

Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.

Hepatitis B and Hepatitis C Viruses infections among ARV- naive and experienced HIV co- infected adults in Addis Ababa, Ethiopia Tsegahun Manyzewal 1,

Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.

Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:

Adequacy of beta-lactam antibiotic dosing in critically ill children on continuous renal replacement therapy: A pilot study. Diaz F 1,2, Benner KW 3, Sewell.

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Treatment of HBV/HCV Coinfection

Emory University School of Medicine Department of Medicine

Effectiveness of Sofosbuvir in terms of sustained virological response at 12 weeks after treatment (SVR12) BETWEEN treatment naïve AND treatment.

The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.

Dr Iyat Abdul Sattar A study on the clinical & serolological markers of HBV among patients with chronic HBV infection in Babylon Dr Monem Makki Alshok.

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Lecture-8 Biopharmaceutics

Vrushali Patwardhan, Dinesh Kumar, Varun Goel, Sarman Singh

Introduction Results Objectives Methods Conclusion Funding

Total Hip Arthroplasty in HIV Positive Patients

DOES HIV/ HEPATITIS COINFECTION AFFECT PEOPLE ACCESSING CARE FOR HIV

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Sexually Transmitted Disease Research

World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.

Coinfection With HIV-1 and HCV—A One-Two Punch

The Aging Liver in the Aging HIV and HCV Patients

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Drug-resistant human immunodefiency virus

Volume 136, Issue 4, Pages (April 2009)

Therapeutic Drug Monitoring chapter 1 part 1

Clinical Pharmacokinetics

Coinfection With HIV-1 and HCV—A One-Two Punch

Dr. Grace Namayanja – Kaye 24 July 2019

Presentation transcript:

POPULATION PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN HCV/HIV OR HBV/HIV CO-INFECTED INDIVIDUALS J.P. Cruz 1,2, D. Matias 1, C. Carvalho 1, J. Morais 2, E. Valadas 3, F. Antunes 3 1) Pharmacology and Pharmacogenetics Laboratorial Unit, Laboratório de Diagnóstico Molecular de Doenças Infecciosas, Faculdade de Medicina da Universidade de Lisboa; 2) iMed.UL – Research Institute for Medicines and Pharmaceutical Sciences; 3) Clinica Universitária de Doenças Infecciosas, Faculdade de Medicina da Universidade de Lisboa. The human immunodeficiency virus (HIV) infection affects more than 40 million individuals worldwide; About one quarter of every HIV-infected individual in developed world is also HCV infected and about one tenth HIV-infected individuals are HBV infected. These co-infections speed up liver disease progression and HIV immune system deterioration; Drug efficacy is dependent on the amount of drug available on site of action. Most antiretroviral drugs are mainly metabolized by liver enzymes. Consequently, the presence of liver disease can influence their efficacy. Pharmacokinetics of antiretroviral drugs in co-infected patients should then be assessed; This study was designed to compare ajusted bayesian pharmacokinetic parameters in co-infected patients versus non co-infected patients. Introduction and purpose Conclusions This preliminary study reveals a small association between some adjusted bayesian pharmacokinetic parameters of antiretroviral drugs and the presence of HCV or HBV co-infection in HIV-infected patients. The lopinavir C min was significantly influenced by the presence of viral hepatitis, however the statistical association of the other adjusted lopinavir pharmacokinetic parameters was not so clear. To disclose further association between the presence of HIV-HCV or HIV-HBV co-infection and antiretroviral pharmacokinetics, more robust data are needed. Discussion A clear association between hepatic enzymes (GPT, GOT, GGT) and co-infection was found (p < 0,05). Also urea plasma levels showed correlation with the presence of viral hepatitis (t-test, p = 0,009) (results not shown). The statistical analysis showed a significant difference in lopinavir C min (MW-test, p < 0,05) with higher mean±SD C min values for co-infected patients (3953±679 ng/mL versus 2383±1389 ng/mL). The adjusted bayesian pharmacokinetic parameters obtained showed no statistically significant differences except for a trend in lopinavir half-life (t-test, p = 0,07). Results 60 HIV-infected patients on triple antiretroviral therapy from the Clinical Ward of Infectious Diseases of Santa Maria Hospital (Lisbon) were enrolled; Blood samples were collected between 8 and 24 hours post-dose (trough concentration / C min ) and analyzed by an HPLC-UV validated method; Individual demographic and clinical data were retrieved; Aboottbase PKS software was used to estimate adjusted bayesian pharmacokinetic parameters (clearance, volume of distribution, elimination rate constant, half-life) and C min ; All results were analyzed in IBM SPSS 17.0 by Mann-Whitney (MW-test) or t-Student tests (t-test). Methods Figure 1 – Study drug distribuition. Table 1 – Study population charateristics. Table 2 – Adjusted bayesian pharmacokinetic parameters for non nucleoside reverse transcriptase inhibitors. Table 3 – Adjusted bayesian pharmacokinetic parameters for protease inhibitors.